Your browser doesn't support javascript.
loading
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger, Emilie; Boccaccino, Alessandra; Lapeyre-Prost, Alexandra; Perret, Audrey; Gallois, Claire; Antista, Maria; Pilla, Lorenzo; Lecomte, Thierry; Scartozzi, Mario; Soularue, Emilie; Salvatore, Lisa; Bourgeois, Vincent; Salati, Massimiliano; Tougeron, David; Evesque, Ludovic; Vaillant, Jean-Nicolas; El-Khoury, Reem; Lonardi, Sara; Cremolini, Chiara; Taieb, Julien.
Afiliación
  • Hafliger E; Department of Gastroenterology and Digestive Oncology, SIRIC CARPEM, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris France.
  • Boccaccino A; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.
  • Lapeyre-Prost A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Perret A; Department of Medical Oncology, Institut Gustave Roussy, Paris, France.
  • Gallois C; Department of Gastroenterology and Digestive Oncology, SIRIC CARPEM, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris France.
  • Antista M; Department of Oncology and Hemato-oncology, Universita' Degli Studi di Milano, Milan, Italy; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Pilla L; Department of Gastroenterology and Digestive Oncology, SIRIC CARPEM, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris France.
  • Lecomte T; Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Tours, Tours, France.
  • Scartozzi M; Medical Oncology, University of Cagliari, University Hospital, Cagliari, Italy.
  • Soularue E; Department of Oncology, Institut Mutualiste Montsouris, Paris, France.
  • Salvatore L; Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.
  • Bourgeois V; Department of Digestive Oncology, Centre Hospitalier de Boulogne sur Mer, France.
  • Salati M; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy.
  • Tougeron D; Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, Poitiers, France.
  • Evesque L; Department of Digestive Oncology, Centre Antoine Lacassagne, Nice, France.
  • Vaillant JN; Department of Medical Oncology, Centre de Cancérologie de La Porte de Saint-Cloud, Paris, France.
  • El-Khoury R; Department of Gastroenterology and Digestive Oncology, SIRIC CARPEM, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris France.
  • Lonardi S; Department of Oncology, Veneto Institute of Oncology IOV and IRCCS, Padua, Italy.
  • Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.
  • Taieb J; Department of Gastroenterology and Digestive Oncology, SIRIC CARPEM, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP-Paris Centre), Université de Paris, Paris France. Electronic address: jtaieb75@gmail.com.
Eur J Cancer ; 168: 34-40, 2022 06.
Article en En | MEDLINE | ID: mdl-35436675
BACKGROUND: Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAFV600E mutated (BRAFm) metastatic colorectal cancer (mCRC). No data are available concerning the efficacy of BRAF inhibitors associated with anti-EGFRs (B + E) in patients previously treated with an anti-EGFR agent. METHODS: We retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and overall survival (OS) were calculated from the start of treatment, and we reported objective response and disease control rates (ORR, DCR; RECIST V1.1). RESULTS: Twenty-five BRAFm mCRC patients were enrolled. Prior to B + E treatment, 4/10/11 patients were treated with 1/2/> 2 previous treatment lines. Ten patients received previous panitumumab, 14 cetuximab, 1 both. Immediate progression with previous anti-EGFR was reported for 7 patients. Anti-BRAF was encorafenib for 21 patients, dabrafenib for 4 patients, with cetuximab for 24 patients and panitumumab for 1 patient. ORR was 40% (10 patients) and DCR was 80% (20 patients). Median PFS and OS were 4.8 months (95% CI, 4.01-7.95) and 10.1 months (95% CI, 7.75-NR). DCR amongst patients with previous primary resistance to anti-EGFR (N = 7) was 100%. Two patients discontinued B + E due to drug-related adverse event. CONCLUSIONS: Though in a limited retrospective series of patients, these results show the efficacy of the combination of anti-BRAF and anti-EGFRs in BRAFm mCRC patients previously treated with an anti-EGFR. The use of this combination should thus not be ruled out in this population with limited therapeutic options.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sulfonamidas / Carbamatos / Neoplasias Colorrectales / Cetuximab Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sulfonamidas / Carbamatos / Neoplasias Colorrectales / Cetuximab Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido